Correspondence 0001193125-24-025275 from Cardlytics, Inc. (CDLX) (CIK 0001666071) (CDLX)
Cardlytics, Inc. (CDLX) (CIK 0001666071)
Date: Feb. 6, 2024 · CIK: 0001666071 · Accession: 0001193125-24-025275
AI Filing Summary & Sentiment
File numbers found in text: 333-276738
Referenced dates: February 2, 2024
Letter
Mark Ballantyne
+1 (703) 456-8084
mballantyne@cooley.com
Via EDGAR
February 6, 2024
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Information Technology
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Jan Woo
Kathleen Krebs
Re:
Cardlytics, Inc.
Registration Statement on Form S-3
Filed January 29, 2024
File No. 333-276738
Ladies and Gentlemen:
On behalf of Cardlytics, Inc. (the “Company”), we are providing this letter in response to the comment (the “Comment”) received from the staff (the “Staff”) of the U.S. Securities and Exchange Commission’s Division of Corporation Finance (the “Commission”) by letter dated February 2, 2024 with respect to the above-referenced Registration Statement on Form S-3 (File No. 333-276738) filed with the Commission on January 29, 2024 (the “Registration Statement”).
Concurrently with the submission of this letter, the Company is filing through the Commission’s Electronic Data Gathering, Analysis and Retrieval (“EDGAR”) system, an amendment to the Registration Statement (the “Amendment”) in response to the Comment and to reflect certain other changes.
Set forth below are the Company’s responses to the Comment. For the Staff’s convenience, the Comment is set forth below in italics.
Form S-3 filed January 29, 2024
General
1. You indicate that you are registering $100 million of securities on behalf of the company and selling securityholders. On page 5, you disclose that “Selling securityholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our securities.” Please revise to identify the initial transaction(s) pursuant to which the securities the selling securityholders are offering were originally sold. Please also clarify that the initial offering was completed and the securities were issued and outstanding prior to filing this registration statement on Form S-3. Revise
United States Securities and Exchange Commission
February 6, 2024
Page
your fee table, prospectus cover page and elsewhere as appropriate to disclose the aggregate number of shares being registered for resale. File a revised legal opinion that covers the securities to be offered for resale by the selling securityholders. Refer to Securities Act Rule 430B(b)(2) and General Instruction II.G of Form S-3. For additional guidance, refer to Questions 228.03 and 228.04 of our Securities Act Rules Compliance and Disclosure Interpretations.
Response to Comment 1:
The Company respectfully acknowledges the Staff’s comment and has revised the Amendment to remove all references to selling securityholders.
Please contact me at (703) 456-8084 or Trey Reilly at (212) 479-6502 with any questions or further comments regarding our responses to the Staff’s Comment.
Sincerely,
Cooley LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP Mark Ballantyne +1 (703) 456-8084 mballantyne@cooley.com Via EDGAR February 6, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Information Technology 100 F Street, N.E. Washington, D.C. 20549 Attention: Jan Woo Kathleen Krebs Re: Cardlytics, Inc. Registration Statement on Form S-3 Filed January 29, 2024 File No. 333-276738 Ladies and Gentlemen: On behalf of Cardlytics, Inc. (the “Company”), we are providing this letter in response to the comment (the “Comment”) received from the staff (the “Staff”) of the U.S. Securities and Exchange Commission’s Division of Corporation Finance (the “Commission”) by letter dated February 2, 2024 with respect to the above-referenced Registration Statement on Form S-3 (File No. 333-276738) filed with the Commission on January 29, 2024 (the “Registration Statement”). Concurrently with the submission of this letter, the Company is filing through the Commission’s Electronic Data Gathering, Analysis and Retrieval (“EDGAR”) system, an amendment to the Registration Statement (the “Amendment”) in response to the Comment and to reflect certain other changes. Set forth below are the Company’s responses to the Comment. For the Staff’s convenience, the Comment is set forth below in italics. Form S-3 filed January 29, 2024 General 1. You indicate that you are registering $100 million of securities on behalf of the company and selling securityholders. On page 5, you disclose that “Selling securityholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our securities.” Please revise to identify the initial transaction(s) pursuant to which the securities the selling securityholders are offering were originally sold. Please also clarify that the initial offering was completed and the securities were issued and outstanding prior to filing this registration statement on Form S-3. Revise 1 United States Securities and Exchange Commission February 6, 2024 Page 2 your fee table, prospectus cover page and elsewhere as appropriate to disclose the aggregate number of shares being registered for resale. File a revised legal opinion that covers the securities to be offered for resale by the selling securityholders. Refer to Securities Act Rule 430B(b)(2) and General Instruction II.G of Form S-3. For additional guidance, refer to Questions 228.03 and 228.04 of our Securities Act Rules Compliance and Disclosure Interpretations. Response to Comment 1: The Company respectfully acknowledges the Staff’s comment and has revised the Amendment to remove all references to selling securityholders. Please contact me at (703) 456-8084 or Trey Reilly at (212) 479-6502 with any questions or further comments regarding our responses to the Staff’s Comment. Sincerely, Cooley LLP /s/ Mark Ballantyne Mark Ballantyne cc: Nick Lynton, Cardlytics, Inc. Trey Reilly, Cooley LLP 2